Navigation Links
Benda Pharmaceutical Files Amendment To Form S-1
Date:5/6/2008

WUHAN, Hubei, China, May 6 /Xinhua-PRNewswire-FirstCall/ -- Benda Pharmaceutical, Inc. (OTC Bulletin Board: BPMA), a China-based pharmaceutical company producing both Gendicine(R), a commercialized gene therapy medicine for the treatment of cancer, and traditional Chinese and conventional medicines, today filed an amendment to the Company's Form S-1 application with the Securities and Exchange Commission ("SEC"). The amendment covers the resale by selling stockholders of up to 17,880,936 shares of common stock, $.001 par value, which includes:

1. 2,106,561 shares of common stock; and

2. 15,774,375 shares of common stock based on 150% of the common stock

issuable upon exercise of outstanding warrants issued at an exercise

price of $0.555 per share in conjunction with the private placements

completed on November 15, 2006 and April 5, 2007.

Mr. Charles Wan, Chief Executive Officer of Benda Pharmaceutical, stated, "We are pleased to file the amendment which takes us one step further to completing our S-1 registration."

Additional information regarding this registration can be found in the Company's Registration Statement on Form S-1/A, as filed with the SEC on May 5, 2008, which can be viewed at http://www.sec.gov .

About Benda Pharmaceutical, Inc.

Benda Pharmaceutical, Inc. ( http://www.bendapharma.com ), a China-based pharmaceutical company, produces traditional Chinese and conventional medicines, as well as Gendicine(R), a commercialized gene therapy medicine for the treatment of cancer.

Safe Harbor Statement

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.


'/>"/>
SOURCE Benda Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
2. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
3. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
4. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
5. Shengtai Pharmaceutical, Inc. Appoints New CFO
6. DermAvance Pharmaceuticals Announces Investment by Ben Franklin Technology Partners of Southeastern Pennsylvania
7. Poniard Pharmaceuticals Announces Upcoming Conference Participation
8. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
9. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008
11. Biopharmaceutical Alliances: Forging Partnerships That Work
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... A best-selling author ... tech companies. “Grit” author Angela Duckworth and her team at Character Lab have ... Cooley, an international law firm with decades of experience supporting high-growth companies in ...
(Date:9/19/2017)... SAN FRANCISCO , Sept. 19, 2017 ... Management Solutions (VLMS) is pleased to announce the strategic ... VTI to provide clients with validation services using the ... a partner, VTI will provide clients with efficient and ... be a marketing partner for the ValGenesis VLMS system. ...
(Date:9/19/2017)... NC (PRWEB) , ... September 19, 2017 , ... ... on band technologies for surgical applications, announced today that two new patents have ... , Michael Albert, MD, Co-Founder of Band-LOK, said, “We continue to explore additional ...
(Date:9/18/2017)... SANTA BARBARA, CALIFORNIA (PRWEB) , ... September 18, ... ... risk management, technological innovation and business process optimization firm for the life sciences ... presentation at the ServiceMax Maximize 2017 conference. , What: Digital Transformation in Medical ...
Breaking Biology Technology:
(Date:6/23/2017)... and ITHACA, N.Y. , ... and Cornell University, a leader in dairy research, today ... bioinformatics designed to help reduce the chances that the ... the onset of this dairy project, Cornell University has ... for Sequencing the Food Supply Chain, a food safety ...
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
Breaking Biology News(10 mins):